Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

Clinical trial NCT01977755 · COMPLETED

Trial details

NCT number: NCT01977755
Sponsor: Zealand Pharma
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Focus of Study is STEMI

Start date: 2013-11-01
Primary completion: 2015-12-20
Enrollment: 591

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.